Textron Inc TXT Positively Positioned to Capture Aerospace Sector Q1 2026 Earnings Tailwinds VNDA Vanda Pharmaceuticals beats Q4 2025 EPS forecasts and grows revenue 87 percent yet shares dip 117 percent today What Dermata DRMAW flagged as biggest challenges ahead DRMAW Q3 Earnings Dermata Warrant Reports No Revenue or Earnings Data MOLN Molecular Q4 2025 EPS tops estimates sending shares up nearly 5 percent in todays session Market Recap Tech leads sector gains as consumer names lag in mild pullback